Expression of cysteine rich 61 and vascular endothelial growth factor genes in patients with myelodysplastic syndromes and their relationship / 中华血液学杂志

<p><b>OBJECTIVE</b>To explore the expression of Cysleine-rich 61(Cyr61) gene in the different subtypes of myelodysplastic syndromes (MDS), and the significance of Cyr61 in the genesis progression, and transformation of MDS and the relationship between Cyr61 and vascular endothelial grown factor (VEGF).</p><p><b>METHODS</b>Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical S-P were used to detect mRNA and protein expressions of Cyr61 and VEGF in bone marrow mononuclear cells (BMMNC) from 28 MDS, 12 acute myeloid leukemia (AML) patients, and 10 normal volunteers.</p><p><b>RESULTS</b>Expressions of Cyr61 and VEGF were higher in MDS and AML patients than in controls (P < 0.05). The expressions of Cyr61 and VEGF were significantly higher in high risk group (0.3998 +/- 0.2647, 0.4775 +/- 0.1342) than that in low risk MDS group (0.2213 +/- 0.1465, 0.2872 +/- 0.2341) (P < 0.05), but no significant difference between high risk MDS and AML patients. Expressions of Cyr61 and VEGF protein were higher in MDS patients than in normal controls (P < 0.05), and were significantly higher in high risk MDS group \[(38.7 +/- 2.9)%, (43.2 +/- 2.7)%\] than in low risk group \[(31.4 +/- 3.1)%, (33.5 +/- 3.4)%\] (P < 0.05). Expressions of Cyr61 and VEGF were significantly correlated (r = 0.8762, P < 0.01).</p><p><b>CONCLUSION</b>Cyr61 and VEGF may play a role in the angiogenesis and pathogenesis of MDS.</p>

Expression of pituitary tumor-transforming gene in patients with multiple myeloma / 中国实验血液学杂志

To explore the expression of pituitary tumor-transforming gene (PTTG) in elderly patients with multiple myeloma (MM) and its relationship with MM, the expressions of PTTG mRNA were detected in bone marrow mononuclear cells (BMMNC) from 33 patients with MM and 10 normal controls by using reverse transcriptase-polymerase chain reaction (RT-PCR). The results showed that the expression of PTTG mRNA in MM patients (0.3415 +/- 0.2172) was significantly higher than that in normal controls (0.0590 +/- 0.0233) (P < 0.05). It is concluded that the overexpression of oncogene PTTG may be related to genesis and progression of MM. It provided a new ideas to study the pathogenesis and gene therapy for MM patients.